Therapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in Adult People with Cystic Fibrosis
Many pwCF under ETI therapy have Cmax values for elexacaftor and ivacaftor above the recommended range, even on reduced doses or before the tmax was reached. This highlights the value of a TDM program. Further pharmacokinetic studies are necessary.
Authors
- Susanne Naehrig (ORCID: https://orcid.org/0000-0002-6525-9190)
- Olaf Sommerburg (ORCID: https://orcid.org/0000-0002-3941-8944)
- Alexandra K. Kunzelmann (ORCID: https://orcid.org/0009-0007-9849-9901)
- Michael Vogeser (ORCID: https://orcid.org/0000-0002-2745-2475)
- Michael Paal (ORCID: https://orcid.org/0000-0001-8831-0238)
- Jürgen Behr (ORCID: https://orcid.org/0000-0002-9151-4829)
- Sarah Sieber
- M. Breuling
- Katharina Habler (ORCID: https://orcid.org/0000-0002-5110-346X)
- Uwe Liebchen (ORCID: https://orcid.org/0000-0002-4375-0923)
- Christina Shad
- Melanie Goetschke
- Johanna Kastenberger
Institutions
- Statistisches Bundesamt (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- LMU Klinikum (DE)
- German Center for Lung Research (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Journal of Personalized Medicine
- Published
- 2024-10-17
- DOI
- https://doi.org/10.3390/jpm14101065
- Citations
- 7
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 2.93
Funders
- Vertex Pharmaceuticals
- Deutsche Forschungsgemeinschaft
- Deutsches Zentrum für Lungenforschung
- CytoSorbents Europe